Synthesis of Vinyl Polymer by Fixing 5-Fluorouracils through Organosilicon Groups via Carbamoyl Bonds and Its Antitumor Activity
Source abstract
Abstract
Some vinyl polymers by fixing 5FUs via carbamoyl bonds on organosilicon groups were synthesized by means of ordinary radical polymerization of the corresponding monomers. These hybrid type vinyl polymers with 5FU and or ganosilicon amine units exhibited significant antitumor activities against p-388 lymphocytic leukemia in mice in vivo (i.p./i.p.). The effects of the molecu lar weight, the hydrophobicity of the polymer carrier, the number of methy lenes in the spacer group, and the presence of silicon on the antitumor activity were investigated. The low molecular weight homopolymer of 5-fluoro-3,4-dihy dro-2,4-dioxo-N-(4,4-dimethyl-4-silahex-5-enyl)-1-(2H)-pyrimidinecarboxamide (KY20), Poly(KY-20), and the copolymer of KY-20 with 2-hydroxyethylmeth acrylate, Poly(KY-20/HEMA), exhibited especially high antitumor activities. The polymers obtained did not display an acute toxicity in the dose range of 25-800 mg/kg. Thus, these polymers were suggested to act as macromolecular prodrugs of 5FU.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Synthetic Organic Chemistry Methods · Cancer Treatment and Pharmacology · Click Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Applied Chemistry Faculty of Engineering Kansai University Suita-shi, Osaka 564, Japan
Yokohama Research Laboratories Chisso Corporation Kanazawa-ku, Yokohama-shi Kanagawa 236, Japan
Cancer Chemotherapy Center Japanese Foundation for Cancer Research Kami-Ikebukuro, Toshima-ku, Tokyo 170, Japan
References (16)
Show source-provided references
1. Waxman, S. and K.J. Scanlon, "Clinical Interpretation & Practice of Cancer Chemotherapy." E. M. Greenspan, ed. New York: Raven Press , p. 39 ( 1982).
2. Heidelberger, C. Cancer Medicine, 2nd Ed. Philadelphia:Lea and Febiger, p. 801 ( 1982).
3. Myers, C.E. · Pharmacol. Rev. · 1981 · 1 · 331
4. Bosch, L. · Cancer Rev. · 1968 · 18 · 335
5. Bounous, G. · Int. J. Chem. Pharmacol. Biopharm · 1978 · 16 · 519
6. 10.1002/pola.1986.08024090310.1002/pola.1986.080240903 ↗
7. 10.1002/marc.1985.03006120510.1002/marc.1985.030061205 ↗
8. 10.1002/pol.1987.14025070210.1002/pol.1987.140250702 ↗
9. 10.1080/0022233870807814010.1080/00222338708078140 ↗
10. Ouchi, T., Y Hagihara and I. Igarashi (unpublished).
11. Ouchi, T. and A. Fujino (unpublished).
12. Toyoshima, S. · Jpn. J. Cancer Chemother · 1981 · 8 · 579
13. Sakurai, T., K. Fukushima, H. Fujita and S. Toyoshima. 13th Proc. Int. Congr. Chemother. , 16:284/135 (1983).
14. Sakurai, T. · 45th Proc. Jpn. Cancer Assocn. · 1986 · 321
15. 10.1246/bcsj.50.240610.1246/bcsj.50.2406 ↗
16. 10.1016/0378-5173(85)90010-910.1016/0378-5173(85)90010-9 ↗